Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385226779> ?p ?o ?g. }
- W4385226779 endingPage "1161" @default.
- W4385226779 startingPage "1161" @default.
- W4385226779 abstract "Glaucoma is a complex, multifactorial optic neuropathy mainly characterized by the progressive loss of retinal ganglion cells (RGCs) and their axons, resulting in a decline of visual function. The pathogenic molecular mechanism of glaucoma is still not well understood, and therapeutic strategies specifically addressing the neurodegenerative component of this ocular disease are urgently needed. Novel immunotherapeutics might overcome this problem by targeting specific molecular structures in the retina and providing direct neuroprotection via different modes of action. Within the scope of this research, the present study showed for the first time beneficial effects of the synthetic CDR1 peptide SCTGTSSDVGGYNYVSWYQ on the viability of RGCs ex vivo in a concentration-dependent manner compared to untreated control explants (CTRL, 50 µg/mL: p < 0.05 and 100 µg/mL: p < 0.001). Thereby, this specific peptide was identified first as a potential biomarker candidate in the serum of glaucoma patients and was significantly lower expressed in systemic IgG molecules compared to healthy control subjects. Furthermore, MS-based co-immunoprecipitation experiments confirmed the specific interaction of synthetic CDR1 with retinal acidic leucine-rich nuclear phosphoprotein 32A (ANP32A; p < 0.001 and log2 fold change > 3), which is a highly expressed protein in neurological tissues with multifactorial biological functions. In silico binding prediction analysis revealed the N-terminal leucine-rich repeat (LRR) domain of ANP32A as a significant binding site for synthetic CDR1, which was previously reported as an important docking site for protein-protein interactions (PPI). In accordance with these findings, quantitative proteomic analysis of the retinae ± CDR1 treatment resulted in the identification of 25 protein markers, which were significantly differentially distributed between both experimental groups (CTRL and CDR1, p < 0.05). Particularly, acetyl-CoA biosynthesis I-related enzymes (e.g., DLAT and PDHA1), as well as cytoskeleton-regulating proteins (e.g., MSN), were highly expressed by synthetic CDR1 treatment in the retina; on the contrary, direct ANP32A-interacting proteins (e.g., NME1 and PPP2R4), as well as neurodegenerative-related markers (e.g., CEND1), were identified with significant lower abundancy in the CDR1-treated retinae compared to CTRL. Furthermore, retinal protein phosphorylation and histone acetylation were also affected by synthetic CDR1, which are both partially controlled by ANP32A. In conclusion, the synthetic CDR1 peptide provides a great translational potential for the treatment of glaucoma in the future by eliciting its neuroprotective mechanism via specific interaction with ANP32A’s N terminal LRR domain." @default.
- W4385226779 created "2023-07-25" @default.
- W4385226779 creator A5003738238 @default.
- W4385226779 creator A5012405272 @default.
- W4385226779 creator A5016720936 @default.
- W4385226779 creator A5040088384 @default.
- W4385226779 creator A5041825129 @default.
- W4385226779 creator A5043777936 @default.
- W4385226779 creator A5059721892 @default.
- W4385226779 creator A5066950709 @default.
- W4385226779 creator A5079455074 @default.
- W4385226779 date "2023-07-22" @default.
- W4385226779 modified "2023-10-02" @default.
- W4385226779 title "Glaucoma-Associated CDR1 Peptide Promotes RGC Survival in Retinal Explants through Molecular Interaction with Acidic Leucine Rich Nuclear Phosphoprotein 32A (ANP32A)" @default.
- W4385226779 cites W1513628006 @default.
- W4385226779 cites W1518948347 @default.
- W4385226779 cites W1527136114 @default.
- W4385226779 cites W1988208648 @default.
- W4385226779 cites W1990082628 @default.
- W4385226779 cites W1990706519 @default.
- W4385226779 cites W1996477699 @default.
- W4385226779 cites W2012034410 @default.
- W4385226779 cites W2029667189 @default.
- W4385226779 cites W2031734331 @default.
- W4385226779 cites W2033822105 @default.
- W4385226779 cites W2034742711 @default.
- W4385226779 cites W2039127036 @default.
- W4385226779 cites W2041528500 @default.
- W4385226779 cites W2049746112 @default.
- W4385226779 cites W2055844410 @default.
- W4385226779 cites W2061007879 @default.
- W4385226779 cites W2073778161 @default.
- W4385226779 cites W2088744527 @default.
- W4385226779 cites W2095319479 @default.
- W4385226779 cites W2096411149 @default.
- W4385226779 cites W2098249834 @default.
- W4385226779 cites W2116149400 @default.
- W4385226779 cites W2134967712 @default.
- W4385226779 cites W2136245934 @default.
- W4385226779 cites W2153598685 @default.
- W4385226779 cites W2153987347 @default.
- W4385226779 cites W2160605010 @default.
- W4385226779 cites W2329037805 @default.
- W4385226779 cites W2399644587 @default.
- W4385226779 cites W2501678270 @default.
- W4385226779 cites W2551551225 @default.
- W4385226779 cites W2608661777 @default.
- W4385226779 cites W2609370534 @default.
- W4385226779 cites W2610352112 @default.
- W4385226779 cites W2624866195 @default.
- W4385226779 cites W2737662919 @default.
- W4385226779 cites W2760093556 @default.
- W4385226779 cites W2765653475 @default.
- W4385226779 cites W2766878655 @default.
- W4385226779 cites W2767014526 @default.
- W4385226779 cites W2778434839 @default.
- W4385226779 cites W2792606167 @default.
- W4385226779 cites W2804439626 @default.
- W4385226779 cites W2888777436 @default.
- W4385226779 cites W2899760200 @default.
- W4385226779 cites W2902010753 @default.
- W4385226779 cites W2911464425 @default.
- W4385226779 cites W2915966434 @default.
- W4385226779 cites W2943285445 @default.
- W4385226779 cites W2947105975 @default.
- W4385226779 cites W2947754092 @default.
- W4385226779 cites W2999995623 @default.
- W4385226779 cites W3010689502 @default.
- W4385226779 cites W3010788579 @default.
- W4385226779 cites W3013594993 @default.
- W4385226779 cites W3014727438 @default.
- W4385226779 cites W3015959740 @default.
- W4385226779 cites W3026323285 @default.
- W4385226779 cites W3048533805 @default.
- W4385226779 cites W3106879760 @default.
- W4385226779 cites W3107626136 @default.
- W4385226779 cites W3112239941 @default.
- W4385226779 cites W3130918919 @default.
- W4385226779 cites W3136762451 @default.
- W4385226779 cites W3154112879 @default.
- W4385226779 cites W3161454284 @default.
- W4385226779 cites W3164446801 @default.
- W4385226779 cites W3168307942 @default.
- W4385226779 cites W3172509480 @default.
- W4385226779 cites W3187287732 @default.
- W4385226779 cites W3193977135 @default.
- W4385226779 cites W3203443932 @default.
- W4385226779 cites W4210957352 @default.
- W4385226779 cites W4224281506 @default.
- W4385226779 cites W4256367673 @default.
- W4385226779 cites W4306156468 @default.
- W4385226779 cites W659392228 @default.
- W4385226779 cites W2967361468 @default.
- W4385226779 doi "https://doi.org/10.3390/biom13071161" @default.
- W4385226779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37509196" @default.
- W4385226779 hasPublicationYear "2023" @default.
- W4385226779 type Work @default.
- W4385226779 citedByCount "0" @default.